Usage
  • 16 views
  • 9 downloads

Challenges for Intellectual Property Management of HIV Vaccine-Related Research and Development: Part 2, The Canadian Context

  • Author(s) / Creator(s)
  • This paper builds upon the key issues identified in Part One of this series of two papers on“Challenges for Intellectual Property Management of HIV Vaccine-Related Research and Development” [hereinafter, Part One]. Following that review of the global literature and consultations with international experts, we consulted with representatives from the CHVI and developed sector-specific interview guides for academic researchers, government, and industry representatives in Canada. We conducted individual or group interviews with key informants in Canada, including CHVI representatives, experts in intellectual property law, management and ethics, as well as academic and private sector HIV vaccine researchers. Here, we present the conclusions from those interviews, a discussion of key concerns, and potential solutions.

  • Date created
    2014-11-14
  • Subjects / Keywords
  • Type of Item
    Research Material
  • DOI
    https://doi.org/10.7939/R39G5GF7C
  • License
    © 2008 Health Law Institute, University of Alberta. This version of this article is open access and can be downloaded and shared. The original authors and source must be cited.
  • Language
  • Citation for previous publication
    • Patten S, Bubela T, Knowles L (2008) Challenges for Intellectual Property Management of HIV Vaccine-Related Research and Development: Part 2, The Canadian Context. Health Law Journal 16: 97-142. [PMID: 19536979] http://hli.ualberta.ca/HealthLawJournals/HealthLawJournalArchive.aspx